Biomarker Testing in Lung Cancer

Bonnie Addario, a lung cancer survivor, explains the importance of comprehensive biomarker testing in patients with lung cancer to treat to target and coverage from insurance companies.

Treating patients with lung cancer by identifying specific biomarkers to use the correct combination therapy and what it means for a biomarker to be actionable.

Ms. Addario shares the promising hope for patients with lung cancer and describes the steps in the process of biomarker testing for patients with lung cancer.

Ms. Addario, lung cancer survivor, encourages patients with non-small cell lung cancer to use all the resources and tools that are available to them.

Allison Collins describes her diagnosis with KRAS-positive non-small cell lung cancer and the symptoms that led her to seek medical attention.

Considerations for the emotional impact of a lung cancer diagnosis and how patients can be supported during their treatment journey.

Dr. Vamsidhar Velcheti provides an expert’s insight on the testing and staging that must be performed during a diagnosis of non-small cell lung cancer.

Allison Collins reflects on the genetic testing she underwent after receiving a non-small cell lung cancer diagnosis and describes the treatment options presented to her at that time.

An in-depth explanation of biomarkers in non-small cell lung cancer, particularly how they can affect the disease and treatment options.

A brief discussion on the importance of enrolling in clinical trials and when that may be an option in non-small cell lung cancer.

Allison Collins shares her experience undergoing a break from therapy after she responded well to treatment for non-small cell lung cancer.

Shared insight on novel treatments for non-small cell lung cancer and how patients should advocate for themselves and seek best available care.

Stephen Liu, MD, and Danielle Hicks describe the purpose and the importance of biomarker testing in non-small cell lung cancer.

Key opinion leaders explain how to discuss biomarker testing with non-small cell lung cancer patients, as well as the common questions they field.

Stephen Liu, MD, and Danielle Hicks illustrate how molecular testing impacts targeted therapy selection in non-small cell lung cancer.

Thought leaders give an overview on KRAS-mutated non-small cell lung cancer and the treatment options available.

Stephen Liu, MD, and Danielle Hicks clarify the importance of involving patients and caregivers in discussions about non-small cell lung cancer molecular testing.